Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc. (PFE) Stock Price & Market Analysis
PFE · NYSE · Pharmaceuticals
$27.40
▼ -$0.1400(-0.51%)4:02 PM ET - vs previous closeQuote as of Nov 20, 2026, 4:02 PM EST
Regular-session close · Nov 20, 2026, 4:02 PM EST.
Long-term rangesAvailable historyHide
Historical range: 2000-11-22–2026-11-20. Earlier trading may not be included.
Loading price chart…
Data dates
PriceAt closeLast traded
FundamentalsLast checked
AnalystLast checked
NewsLatest item
What matters next
Next important events
- Feb 2, 2027Next earnings (est.)Estimated
Countdown
72 days out
Reported fundamentals
PFE financial overview
Annual revenue
USD 62.58B
Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.
Revenue change
-1.6%
Change versus the fiscal year ended Dec 31, 2024.
Net profit margin
12.4%
Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.
These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.
Company · ProfileAbout Pfizer Inc. (PFE)Sector, leadership, and how Pfizer Inc. earns its revenue.Healthcare
Pfizer Inc.
NYSE · PFE · US
Company overview as of Nov 22, 2026.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Headquarters
- New York, NY, United States
- Country
- US
- Founded
- 1849
- Employees
- 75,000
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Exchange
- NYSE
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.
Narrative versus numbers
Demand is expanding
Contradicting observation: -0.4%
Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 27, 2026
Growth produces accounting profit
Supporting observation: 6.3%
Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 22, 2026, 12:10 AM EST
The business generates cash after investment
Supporting observation: USD 4.8B
Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 27, 2026
These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.
Operating measures
- Revenue
- $16.58Bquarter ended Sep 27, 2026
- EPS
- $0.56quarter ended Sep 27, 2026
- Capital expenditure
- $573.00Mquarter ended Sep 27, 2026
- Free cash flow
- $4.80Bquarter ended Sep 27, 2026
- Free cash flow margin
- 29.0%quarter ended Sep 27, 2026
- Operating cash / net income
- 1.66×quarter ended Sep 27, 2026
- Revenue growth year over year
- -0.4%quarter ended Sep 27, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.
Governance & sustainability
Market closed
Regular hours: 9:30 AM–4:00 PM America/New_York
Next open: 2026-11-23 · 9:30 AM America/New_York
Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.
Shortcuts
With research tools focused: / search · W watchlist · C compare · F financials · E earnings · N news · T technicals · Esc close